University of California San Francisco

Laura Van 'T Veer, PhD
Laura Van 'T Veer, PhD

Professor, Laboratory Medicine

Associate Director Applied Genomics

Address

2340 Sutter Street, #N415
San Francisco, CA 94115
United States

Email: [email protected]
Phone: 415-476-6023

Education

Institution Degree Dept or School End Date
University of Leiden, Leiden, Netherlands PhD Medicine, Oncogene Activation and Tumorigenesis 1989
University of Amsterdam, Amsterdam, Netherlands MSc Experimental Oncology 1984
University of Amsterdam, Amsterdam, Netherlands BSc Biology, Molecular Oncology 1980

Awards & Honors

Award Conferred By Date
European Inventor Award 2015 European Patent Office (EPO) 2015
Second Prize, European Union Prize for Women Innovators European Union Prize for Women Innovators 2014
AACC Outstanding Speaker Award AACC 2012
First Annual Harry and Edith Gladstein Award, Indiana University, School of Medicine 2009
Breast Cancer Research Fund (BCRF-Pink Ribbon US) grant award Breast Cancer Research Fund 2007/2011
Lifetime Achievement Award for Translational Research in Breast Cancer European Society Medical Oncology (ESMO) 2007
Van der Scheuren award lecture for European Breast Cancer Research EBCC5 2006
Medal of Honor International Agency for Research on Cancer (IARC) , Lyon, France 2005
Postdoctoral Fellowship The Irvington Institute for Medical Research, New York, USA 1991/1994
Long-term Fellowship NWO The Netherlands Organization for Scientific Research, 's-Gravenhage, The Netherlands 1989/1990

Grants and Funding

  • Strategy for combining circulating tumor DNA (ctDNA) and magnetic resonance imaging (MRI) measures of tumor burden for prediction of response and outcome in neoadjuvant-treated early breast cancer | NIH | 2020-12-03 - 2025-11-30 | Role: Principal Investigator
  • Center for Big Data in Translational Genomics | NIH | 2014-09-29 - 2021-08-31 | Role: Co-Principal Investigator
  • Integrative signaling models to decipher complex cancer phenotypes | NIH | 2012-08-08 - 2017-07-31 | Role: Co-Principal Investigator
  • Leukocyte Biomarkers for Predicting Human Breast Cancer Outcomes | NIH | 2011-09-23 - 2017-07-31 | Role: Co-Principal Investigator
  • SPORE in Breast Cancer | NIH | 1992-09-30 - 2013-11-30 | Role: Principal Investigator

Publications

MOST RECENT PUBLICATIONS FROM A TOTAL OF 63
  1. The 70-gene prognosis signature predicts early metastasis in breast cancer patients between 55 and 70 years of age.
    Mook S, Schmidt MK, Weigelt B, Kreike B, Eekhout I, van de Vijver MJ, Glas AM, Floore A, Rutgers EJT, van 't Veer LJ| | PubMed
  2. Clinical relevance of the triple-negative breast cancer concept: genetic basis and clinical utility of the concept.
    Linn SC, Van 't Veer LJ| | PubMed
  3. A comprehensive analysis of prognostic signatures reveals the high predictive capacity of the proliferation, immune response and RNA splicing modules in breast cancer.
    Reyal F, van Vliet MH, Armstrong NJ, Horlings HM, de Visser KE, Kok M, Teschendorff AE, Mook S, van 't Veer L, Caldas C, Salmon RJ, van de Vijver MJ, Wessels LF| | PubMed
  4. Recent advances in metastasis research.
    Molloy T, van 't Veer LJ| | PubMed
  5. The spectrum of ATM missense variants and their contribution to contralateral breast cancer.
    Broeks A, Braaf LM, Huseinovic A, Schmidt MK, Russell NS, van Leeuwen FE, Hogervorst FB, Van 't Veer LJ| | PubMed
  6. Identification of women with an increased risk of developing radiation-induced breast cancer: a case only study.
    Broeks A, Braaf LM, Huseinovic A, Nooijen A, Urbanus J, Hogervorst FB, Schmidt MK, Klijn JG, Russell NS, Van Leeuwen FE, Van 't Veer LJ| | PubMed
  7. Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial.
    Bogaerts J, Cardoso F, Buyse M, Braga S, Loi S, Harrison JA, Bines J, Mook S, Decker N, Ravdin P, Therasse P, Rutgers E, van 't Veer LJ, Piccart M, TRANSBIG consortium| | PubMed
  8. Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group.
    Rebbeck TR, Friebel T, Wagner T, Lynch HT, Garber JE, Daly MB, Isaacs C, Olopade OI, Neuhausen SL, van 't Veer L, Eeles R, Evans DG, Tomlinson G, Matloff E, Narod SA, Eisen A, Domchek S, Armstrong K, Weber BL, PROSE Study Group| | PubMed
  9. Breast cancer metastasis: markers and models.
    Weigelt B, Peterse JL, van 't Veer LJ| | PubMed
  10. Laura van 't Veer, PhD: bringing tumor gene profiles into the clinic. Interview.
    van 't Veer L| | PubMed
63
View all 63 Publications
MOST RECENT PUBLICATIONS FROM A TOTAL OF 63
  1. The San Francisco Cancer Initiative: A Community Effort To Reduce The Population Burden Of Cancer.
    Hiatt RA, Sibley A, Fejerman L, Glantz S, Nguyen T, Pasick R, Palmer N, Perkins A, Potter MB, Somsouk M, Vargas RA, van 't Veer LJ, Ashworth A| | PubMed
  2. Immunohistochemical versus molecular (BluePrint and MammaPrint) subtyping of breast carcinoma. Outcome results from the EORTC 10041/BIG 3-04 MINDACT trial.
    Viale G, de Snoo FA, Slaets L, Bogaerts J, van 't Veer L, Rutgers EJ, Piccart-Gebhart MJ, Stork-Sloots L, Glas A, Russo L, Dell'Orto P, Tryfonidis K, Litière S, Cardoso F, MINDACT investigators| | PubMed
  3. Heterogeneous drug penetrance of veliparib and carboplatin measured in triple negative breast tumors.
    Bartelink IH, Prideaux B, Krings G, Wilmes L, Lee PRE, Bo P, Hann B, Coppé JP, Heditsian D, Swigart-Brown L, Jones EF, Magnitsky S, Keizer RJ, de Vries N, Rosing H, Pawlowska N, Thomas S, Dhawan M, Aggarwal R, Munster PN, Esserman LJ, Ruan W, Wu AHB, Yee D, Dartois V, Savic RM, Wolf DM, van 't Veer L| | PubMed
  4. The BRCA1ness signature is associated significantly with response to PARP inhibitor treatment versus control in the I-SPY 2 randomized neoadjuvant setting.
    Severson TM, Wolf DM, Yau C, Peeters J, Wehkam D, Schouten PC, Chin SF, Majewski IJ, Michaut M, Bosma A, Pereira B, Bismeijer T, Wessels L, Caldas C, Bernards R, Simon IM, Glas AM, Linn S, van 't Veer L| | PubMed
  5. Tamoxifen therapy benefit for patients with 70-gene signature high and low risk.
    van 't Veer LJ, Yau C, Yu NY, Benz CC, Nordenskjöld B, Fornander T, Stål O, Esserman LJ, Lindström LS| | PubMed
  6. 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer.
    Cardoso F, van't Veer LJ, Bogaerts J, Slaets L, Viale G, Delaloge S, Pierga JY, Brain E, Causeret S, DeLorenzi M, Glas AM, Golfinopoulos V, Goulioti T, Knox S, Matos E, Meulemans B, Neijenhuis PA, Nitz U, Passalacqua R, Ravdin P, Rubio IT, Saghatchian M, Smilde TJ, Sotiriou C, Stork L, Straehle C, Thomas G, Thompson AM, van der Hoeven JM, Vuylsteke P, Bernards R, Tryfonidis K, Rutgers E, Piccart M, MINDACT Investigators| | PubMed
  7. TP53 germline mutation testing in 180 families suspected of Li-Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes.
    Ruijs MW, Verhoef S, Rookus MA, Pruntel R, van der Hout AH, Hogervorst FB, Kluijt I, Sijmons RH, Aalfs CM, Wagner A, Ausems MG, Hoogerbrugge N, van Asperen CJ, Gomez Garcia EB, Meijers-Heijboer H, Ten Kate LP, Menko FH, van 't Veer LJ| | PubMed
  8. The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer.
    Knauer M, Mook S, Rutgers EJ, Bender RA, Hauptmann M, van de Vijver MJ, Koornstra RH, Bueno-de-Mesquita JM, Linn SC, van 't Veer LJ| | PubMed
  9. Radiation-associated breast tumors display a distinct gene expression profile.
    Broeks A, Braaf LM, Wessels LF, van de Vijver M, De Bruin ML, Stovall M, Russell NS, van Leeuwen FE, Van 't Veer LJ| | PubMed
  10. Complex landscapes of somatic rearrangement in human breast cancer genomes.
    Stephens PJ, McBride DJ, Lin ML, Varela I, Pleasance ED, Simpson JT, Stebbings LA, Leroy C, Edkins S, Mudie LJ, Greenman CD, Jia M, Latimer C, Teague JW, Lau KW, Burton J, Quail MA, Swerdlow H, Churcher C, Natrajan R, Sieuwerts AM, Martens JW, Silver DP, Langerød A, Russnes HE, Foekens JA, Reis-Filho JS, van 't Veer L, Richardson AL, Børresen-Dale AL, Campbell PJ, Futreal PA, Stratton MR| | PubMed
  11. The 70-gene prognosis signature predicts early metastasis in breast cancer patients between 55 and 70 years of age.
    Mook S, Schmidt MK, Weigelt B, Kreike B, Eekhout I, van de Vijver MJ, Glas AM, Floore A, Rutgers EJT, van 't Veer LJ| | PubMed
  12. Clinical relevance of the triple-negative breast cancer concept: genetic basis and clinical utility of the concept.
    Linn SC, Van 't Veer LJ| | PubMed
  13. A comprehensive analysis of prognostic signatures reveals the high predictive capacity of the proliferation, immune response and RNA splicing modules in breast cancer.
    Reyal F, van Vliet MH, Armstrong NJ, Horlings HM, de Visser KE, Kok M, Teschendorff AE, Mook S, van 't Veer L, Caldas C, Salmon RJ, van de Vijver MJ, Wessels LF| | PubMed
  14. Recent advances in metastasis research.
    Molloy T, van 't Veer LJ| | PubMed
  15. The spectrum of ATM missense variants and their contribution to contralateral breast cancer.
    Broeks A, Braaf LM, Huseinovic A, Schmidt MK, Russell NS, van Leeuwen FE, Hogervorst FB, Van 't Veer LJ| | PubMed
  16. Identification of women with an increased risk of developing radiation-induced breast cancer: a case only study.
    Broeks A, Braaf LM, Huseinovic A, Nooijen A, Urbanus J, Hogervorst FB, Schmidt MK, Klijn JG, Russell NS, Van Leeuwen FE, Van 't Veer LJ| | PubMed
  17. Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial.
    Bogaerts J, Cardoso F, Buyse M, Braga S, Loi S, Harrison JA, Bines J, Mook S, Decker N, Ravdin P, Therasse P, Rutgers E, van 't Veer LJ, Piccart M, TRANSBIG consortium| | PubMed
  18. Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group.
    Rebbeck TR, Friebel T, Wagner T, Lynch HT, Garber JE, Daly MB, Isaacs C, Olopade OI, Neuhausen SL, van 't Veer L, Eeles R, Evans DG, Tomlinson G, Matloff E, Narod SA, Eisen A, Domchek S, Armstrong K, Weber BL, PROSE Study Group| | PubMed
  19. Breast cancer metastasis: markers and models.
    Weigelt B, Peterse JL, van 't Veer LJ| | PubMed
  20. Laura van 't Veer, PhD: bringing tumor gene profiles into the clinic. Interview.
    van 't Veer L| | PubMed
  21. Insulin-like growth factor (IGF)-system mRNA quantities in normal and tumor breast tissue of women with sporadic and familial breast cancer risk.
    Voskuil DW, Bosma A, Vrieling A, Rookus MA, van 't Veer LJ| | PubMed
  22. [Genetic research with stored human tissue: a coding procedure with optimal use of information and protection of privacy].
    Schmidt MK, van Leeuwen FE, Klaren HM, Tollenaar RA, van 't Veer LJ| | PubMed
  23. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group.
    Rebbeck TR, Friebel T, Lynch HT, Neuhausen SL, van 't Veer L, Garber JE, Evans GR, Narod SA, Isaacs C, Matloff E, Daly MB, Olopade OI, Weber BL| | PubMed
  24. Are ATM mutations 7271T-->G and IVS10-6T-->G really high-risk breast cancer-susceptibility alleles?
    Szabo CI, Schutte M, Broeks A, Houwing-Duistermaat JJ, Thorstenson YR, Durocher F, Oldenburg RA, Wasielewski M, Odefrey F, Thompson D, Floore AN, Kraan J, Klijn JG, van den Ouweland AM, Wagner TM, Devilee P, Simard J, van 't Veer LJ, Goldgar DE, Meijers-Heijboer H| | PubMed
  25. Expression of a novel lacrimal gland gene lacritin in human breast tissues.
    Weigelt B, Bosma AJ, van 't Veer LJ| | PubMed
  26. Marker genes for circulating tumour cells predict survival in metastasized breast cancer patients.
    Weigelt B, Bosma AJ, Hart AA, Rodenhuis S, van 't Veer LJ| | PubMed
  27. [From gene to disease; ataxia telangiectasia].
    Broeks A, van 't Veer LJ, Ottenheim C, Hiel JA, Kleijer WJ, Weemaes C| | PubMed
  28. Expression profiling predicts outcome in breast cancer.
    van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Bernards R, Friend SH| | PubMed
  29. Detection of circulating breast tumor cells by differential expression of marker genes.
    Bosma AJ, Weigelt B, Lambrechts AC, Verhagen OJ, Pruntel R, Hart AA, Rodenhuis S, van 't Veer LJ| | PubMed
  30. Gene expression profiling predicts clinical outcome of breast cancer.
    van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R, Friend SH| | PubMed
  31. The microarray way to tailored cancer treatment.
    Van 't Veer LJ, De Jong D| | PubMed
  32. ATM-heterozygous germline mutations contribute to breast cancer-susceptibility.
    Broeks A, Urbanus JH, Floore AN, Dahler EC, Klijn JG, Rutgers EJ, Devilee P, Russell NS, van Leeuwen FE, van 't Veer LJ| | PubMed
  33. Differences in estrogen receptor alpha variant messenger RNAs between normal human breast tissue and primary breast carcinomas.
    van Dijk MA, Hart AA, van 't Veer LJ| | PubMed
  34. Translational research offers individually tailored treatments for cancer patients.
    Bartelink H, Begg AC, Martin JC, van Dijk M, Moonen L, van 't Veer LJ, Van de Vaart P, Verheij M| | PubMed
  35. Characteristics of small breast and/or ovarian cancer families with germline mutations in BRCA1 and BRCA2.
    Ligtenberg MJ, Hogervorst FB, Willems HW, Arts PJ, Brink G, Hageman S, Bosgoed EA, Van der Looij E, Rookus MA, Devilee P, Vos EM, Wigbout G, Struycken PM, Menko FH, Rutgers EJ, Hoefsloot EH, Mariman EC, Brunner HG, Van 't Veer LJ| | PubMed
  36. [Epstein-Barr virus in a donor kidney as a cause of non-Hodgkin lymphoma].
    Kersten MJ, Surachno S, Koopman MG, van 't Veer LJ, Pals ST, van Oers MH| | PubMed
  37. [The role of genetic factors in the development of gastric cancer].
    Taal BG, van Loon HJ, Kahn N, de Jong D, Vasen HF, van 't Veer LJ| | PubMed
  38. Towards prediction and modulation of treatment response.
    Bartelink H, Begg A, Martin JC, van Dijk M, van 't Veer L, van der Vaart P, Verheij M| | PubMed
  39. The detection of minimal numbers of contaminating epithelial tumor cells in blood or bone marrow: use, limitations and future of RNA-based methods.
    Lambrechts AC, van 't Veer LJ, Rodenhuis S| | PubMed
  40. The use of 4-aminobiphenyl hemoglobin adducts and aromatic DNA adducts in lymphocytes of smokers as biomarkers of exposure.
    Dallinga JW, Pachen DM, Wijnhoven SW, Breedijk A, van 't Veer L, Wigbout G, van Zandwijk N, Maas LM, van Agen E, Kleinjans JC, van Schooten FJ| | PubMed
  41. Differences in aromatic-DNA adduct levels between alveolar macrophages and subpopulations of white blood cells from smokers.
    Godschalk RW, Maas LM, Van Zandwijk N, van 't Veer LJ, Breedijk A, Borm PJ, Verhaert J, Kleinjans JC, van Schooten FJ| | PubMed
  42. Multiple malignancies in a patient with bilateral retinoblastoma.
    Ceha HM, Balm AJ, de Jong D, van 't Veer LJ| | PubMed
  43. ATM germline mutations in classical ataxia-telangiectasia patients in the Dutch population.
    Broeks A, de Klein A, Floore AN, Muijtjens M, Kleijer WJ, Jaspers NG, van 't Veer LJ| | PubMed
  44. The role of prognostic factors and oncogenes in the detection and management of non-small-cell lung cancer.
    Van Zandwijk N, Van 't Veer LJ| | PubMed
  45. A method to monitor mRNA levels in human breast tumor cells obtained by fine-needle aspiration.
    de Lange MS, Top B, Lambrechts C, Maas RA, Peterse HL, Mooi WJ, van 't Veer LJ, Rodenhuis S| | PubMed
  46. BRCA1 genomic deletions are major founder mutations in Dutch breast cancer patients.
    Petrij-Bosch A, Peelen T, van Vliet M, van Eijk R, Olmer R, Drüsedau M, Hogervorst FB, Hageman S, Arts PJ, Ligtenberg MJ, Meijers-Heijboer H, Klijn JG, Vasen HF, Cornelisse CJ, van 't Veer LJ, Bakker E, van Ommen GJ, Devilee P| | PubMed
  47. A functional assay in yeast for the human estrogen receptor displays wild-type and variant estrogen receptor messenger RNAs present in breast carcinoma.
    van Dijk MA, Floore AN, Kloppenborg KI, van 't Veer LJ| | PubMed
  48. Oligoclonal peripheral T-cell lymphocytosis as a result of aberrant T-cell development in a cortical thymoma.
    de Jong D, Richel DJ, Schenkeveld C, Boerrigter L, van 't Veer LJ| | PubMed
  49. The XPB subunit of repair/transcription factor TFIIH directly interacts with SUG1, a subunit of the 26S proteasome and putative transcription factor.
    Weeda G, Rossignol M, Fraser RA, Winkler GS, Vermeulen W, van 't Veer LJ, Ma L, Hoeijmakers JH, Egly JM| | PubMed
  50. Identification of Bmi1-interacting proteins as constituents of a multimeric mammalian polycomb complex.
    Alkema MJ, Bronk M, Verhoeven E, Otte A, van 't Veer LJ, Berns A, van Lohuizen M| | PubMed
  51. RalGDS-like factor (Rlf) is a novel Ras and Rap 1A-associating protein.
    Wolthuis RM, Bauer B, van 't Veer LJ, de Vries-Smits AM, Cool RH, Spaargaren M, Wittinghofer A, Burgering BM, Bos JL| | PubMed
  52. E2F-5, a new E2F family member that interacts with p130 in vivo.
    Hijmans EM, Voorhoeve PM, Beijersbergen RL, van 't Veer LJ, Bernards R| | PubMed
  53. Activation of the mas oncogene involves coupling to human alphoid sequences.
    van 't Veer LJ, van der Feltz MJ, van den Berg-Bakker CA, Cheng NC, Hermens RP, van Oorschot DA, Kievits T, Schrier PI| | PubMed
  54. TATA-binding protein and the retinoblastoma gene product bind to overlapping epitopes on c-Myc and adenovirus E1A protein.
    Hateboer G, Timmers HT, Rustgi AK, Billaud M, van 't Veer LJ, Bernards R| | PubMed
  55. N-myc suppresses major histocompatibility complex class I gene expression through down-regulation of the p50 subunit of NF-kappa B.
    van 't Veer LJ, Beijersbergen RL, Bernards R| | PubMed
  56. Structure and expression of major histocompatibility complex-binding protein 2, a 275-kDa zinc finger protein that binds to an enhancer of major histocompatibility complex class I genes.
    van 't Veer LJ, Lutz PM, Isselbacher KJ, Bernards R| | PubMed
  57. Sensitivity of melanoma cell lines to natural killer cells: a role for oncogene-modulated HLA class I expression?
    Schrier PI, Versteeg R, Peltenburg LT, Plomp AC, van 't Veer LJ, Krüse-Wolters KM| | PubMed
  58. Two genes encode factors with NF-kappa B- and H2TF1-like DNA-binding properties.
    Rustgi AK, Van 't Veer LJ, Bernards R| | PubMed
  59. N-ras mutations in human cutaneous melanoma from sun-exposed body sites.
    van 't Veer LJ, Burgering BM, Versteeg R, Boot AJ, Ruiter DJ, Osanto S, Schrier PI, Bos JL| | PubMed
  60. cis-diamminedichloroplatinum(II)-resistant sublines derived from two human ovarian tumor cell lines.
    Kuppen PJ, Schuitemaker H, van 't Veer LJ, de Bruijn EA, van Oosterom AT, Schrier PI| | PubMed
  61. ras oncogene activation in human ovarian carcinoma.
    van 't Veer LJ, Hermens R, van den Berg-Bakker LA, Cheng NC, Fleuren GJ, Bos JL, Cleton FJ, Schrier PI| | PubMed
  62. High frequency of mas oncogene activation detected in the NIH3T3 tumorigenicity assay.
    van 't Veer LJ, van den Berg-Bakker LA, Hermens RP, Deprez RL, Schrier PI| | PubMed
  63. Molecular cloning and chromosomal assignment of the human homolog of int-1, a mouse gene implicated in mammary tumorigenesis.
    van 't Veer LJ, van Kessel AG, van Heerikhuizen H, van Ooyen A, Nusse R| | PubMed